New Method Using DNA Nanoballs to Revolutionize Pathogen Detection
|
By LabMedica International staff writers Posted on 08 Sep 2023 |

Throughout the recent COVID-19 pandemic, protein-based diagnostics played a significant role in rapid testing. However, developing high-quality antibodies for these methods is time-consuming. In contrast, nucleic acid-based approaches offer advantages in terms of development ease, sensitivity, and flexibility. Scientists have now pioneered a novel technique using DNA Nanoballs for pathogen detection that could simplify nucleic acid testing and revolutionize pathogen identification. Their research could pave the way for a simple electronic-based test to quickly and affordably identify various nucleic acids in diverse scenarios.
The methodology developed by researchers at Karolinska Institute (Stockholm, Sweden) combined Molecular Biology (specifically DNA Nanoball generation) with electronics (electric impedance-based quantification) to create this groundbreaking detection tool. They are cautiously optimistic about its potential to identify a range of pathogenic agents in real-world settings. The team modified an isothermal DNA amplification reaction called LAMP to produce tiny DNA nanoballs measuring 1-2μM if the pathogen was present in the sample. These nanoballs are then guided through tiny channels and electrically identified as they pass between two electrodes. The method has demonstrated impressive sensitivity, capable of detecting as few as 10 target molecules, and provides rapid results in under an hour using a compact, stationary system.
This label-free detection method has the potential to accelerate the development of new diagnostic kits. By combining affordable mass-produced electronics with lyophilized reagents, it could become a cost-effective, widely accessible, and scalable point-of-care device. Currently, the research team is actively exploring applications in fields such as environmental monitoring, food safety, virus detection, and antimicrobial resistance testing. They are also considering licensing options and establishing a startup to leverage this technology, having recently applied for a patent.
“Fast and accurate detection of genetic material is key for diagnosis, especially so in response to the emergence of novel pathogens,” said principal investigator Vicent Pelechano.
Related Links:
Karolinska Institute
Latest Molecular Diagnostics News
- Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
- Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
- Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
- Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
- Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
- AI Reveals Immune Response Biomarkers Linked to Ebola Survival
- Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
- WHO Adds First Bundibugyo Ebola Molecular Test to Emergency Use Listing
- Blood Test Helps Guide Post-Surgical Treatment in Metastatic Colorectal Cancer
- Study Supports Earlier Genetic Testing for Hereditary Breast and Ovarian Cancer
- Noninvasive Biomarkers Advance Colorectal Cancer Risk Assessment
- Rapid Brush Biopsy Test Detects Oral Cancer in One Hour
- AI-Driven Blood Test Enhances Early Detection of Multiple Cancers
- Interpretable AI Tool Improves Prediction of Immunotherapy Response
- Blood Test Using Circular RNA Biomarkers Predicts Alzheimer’s Progression
- At-Home PCR Test Detects Flu and COVID-19 in 30 Minutes
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read morePathology
view channel
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more




.jpg)



